Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) has earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $10.78.
Several equities analysts have commented on the company. The Goldman Sachs Group increased their target price on Maravai LifeSciences from $7.00 to $8.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. Wells Fargo & Company started coverage on Maravai LifeSciences in a research report on Tuesday, August 27th. They set an “overweight” rating and a $10.00 price objective for the company. UBS Group raised their price objective on Maravai LifeSciences from $8.50 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, August 8th. Morgan Stanley downgraded Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $11.00 to $10.00 in a research report on Tuesday, August 13th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $15.00 price objective on shares of Maravai LifeSciences in a research report on Friday, August 16th.
View Our Latest Analysis on Maravai LifeSciences
Institutional Investors Weigh In On Maravai LifeSciences
Maravai LifeSciences Price Performance
Maravai LifeSciences stock opened at $7.83 on Thursday. The company has a current ratio of 10.00, a quick ratio of 9.28 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $1.97 billion, a PE ratio of -7.99 and a beta of 0.01. Maravai LifeSciences has a 12 month low of $4.52 and a 12 month high of $11.56. The stock has a 50-day moving average price of $8.77 and a two-hundred day moving average price of $8.61.
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $73.40 million during the quarter, compared to the consensus estimate of $71.64 million. Maravai LifeSciences had a negative net margin of 47.41% and a negative return on equity of 4.78%. Maravai LifeSciences’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.06) earnings per share. Analysts expect that Maravai LifeSciences will post -0.17 EPS for the current year.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Stories
- Five stocks we like better than Maravai LifeSciences
- How to Plot Fibonacci Price Inflection Levels
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- 3 Small Caps With Big Return Potential
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- NYSE Stocks Give Investors a Variety of Quality Options
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.